Clinical and translational medicine · 2026
Macrophage Cluster of Differentiation 163 promotes post-infarction cardiac repair and preserves left ventricular function via osteopontin.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jingyu, Chen Linjian, Huang Wei, Wang Gang, Wang Lin, Mei Wanchun, Ni Wei, Liu Yang, Ding Licheng, Ge Xiaofeng, Li Zhaokai, Yu Jing, Huang Shufen, Lin Jiayi, Chen Yifan, Cai Binni, Zhang Peng, Dai Cuilian, Liu Binbin
Аннотация
BACKGROUND: Cardiac macrophages (cMacs) have been implicated in myocardial repair following myocardial infarction (MI), yet their therapeutic potential in ischaemic cardiomyopathy (ICM) remains limited by an incomplete understanding of their molecular regulation. Cluster of Differentiation 163 (CD163) is highly expressed in these macrophages, yet its functional role in regulating post-MI cardiac repair remains unknown.
METHODS: A cross-sectional clinical study was conducted to assess the association between circulating soluble CD163 concentration and heart failure due to ICM. To investigate the functional contribution of CD163 in ICM, wild-type (WT) and Cd163- / - mice were subjected to permanent ligation of the left anterior descending coronary artery. Single-cell RNA sequencing was employed to analyse transcriptional changes in cardiac immune cells. Recombinant osteopontin (OPN) and CD163 were administered to assess their therapeutic effect in Cd163- / - mice.
RESULTS: Circulating soluble CD163 levels were markedly elevated in patients with ICM-induced heart failure compared with individuals without heart failure (median difference 34.5 ng/mL, IQR 13.6-54.6 ng/mL, p = .002) and showed a positive correlation with the extent of systolic dysfunction and left ventricular (LV) dilation. Cd163- / - mice displayed aggravated LV systolic dysfunction, reduced ejection fraction and fractional shortening, impaired myocardial strain and reduced relative wall thickness post-MI. Recombinant CD163 protein could reverse systolic dysfunction and LV dilation in Cd163- / - mice after MI. CD163 was predominantly expressed in CCR2- resident cMacs, and CD163 deficiency altered transcriptional programmes of macrophages without affecting their polarization status, with enrichment in cytokine signalling and extracellular matrix-related pathways. Spp1 (OPN) expression was significantly downregulated in Cd163- / - hearts under both sham and MI conditions. Administration of recombinant OPN improved systolic function, reduced ventricular dilation, decreased fibrotic scar size and restored the elastin-to-collagen ratio in Cd163- / - mice.
CONCLUSIONS: In cMacs, CD163 contributes to post-MI repair by upregulating OPN expression, which in turn helps maintain systolic function.
KEY POINTS: Soluble CD163 is elevated in ICM and correlates with LV dysfunction. Cd163- / - mice show worsened post-MI systolic dysfunction and dilation. Recombinant CD163 reverses dysfunction in Cd163- / - mice. OPN restores function and improves LV structure in Cd163- / - mice.
METHODS: A cross-sectional clinical study was conducted to assess the association between circulating soluble CD163 concentration and heart failure due to ICM. To investigate the functional contribution of CD163 in ICM, wild-type (WT) and Cd163- / - mice were subjected to permanent ligation of the left anterior descending coronary artery. Single-cell RNA sequencing was employed to analyse transcriptional changes in cardiac immune cells. Recombinant osteopontin (OPN) and CD163 were administered to assess their therapeutic effect in Cd163- / - mice.
RESULTS: Circulating soluble CD163 levels were markedly elevated in patients with ICM-induced heart failure compared with individuals without heart failure (median difference 34.5 ng/mL, IQR 13.6-54.6 ng/mL, p = .002) and showed a positive correlation with the extent of systolic dysfunction and left ventricular (LV) dilation. Cd163- / - mice displayed aggravated LV systolic dysfunction, reduced ejection fraction and fractional shortening, impaired myocardial strain and reduced relative wall thickness post-MI. Recombinant CD163 protein could reverse systolic dysfunction and LV dilation in Cd163- / - mice after MI. CD163 was predominantly expressed in CCR2- resident cMacs, and CD163 deficiency altered transcriptional programmes of macrophages without affecting their polarization status, with enrichment in cytokine signalling and extracellular matrix-related pathways. Spp1 (OPN) expression was significantly downregulated in Cd163- / - hearts under both sham and MI conditions. Administration of recombinant OPN improved systolic function, reduced ventricular dilation, decreased fibrotic scar size and restored the elastin-to-collagen ratio in Cd163- / - mice.
CONCLUSIONS: In cMacs, CD163 contributes to post-MI repair by upregulating OPN expression, which in turn helps maintain systolic function.
KEY POINTS: Soluble CD163 is elevated in ICM and correlates with LV dysfunction. Cd163- / - mice show worsened post-MI systolic dysfunction and dilation. Recombinant CD163 reverses dysfunction in Cd163- / - mice. OPN restores function and improves LV structure in Cd163- / - mice.